

Study References

Neurological Wellness

Alexander, C., & Vasefi, M. (2021). Cannabidiol and the corticoraphe circuit in post-traumatic stress disorder. *IBRO Neuroscience Reports*, 11, 88–102. <https://doi.org/10.1016/j.ibneur.2021.08.001>

Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. *Neurotherapeutics*, 12(4), 825–836. <https://doi.org/10.1007/s13311-015-0387-1>

Costa, A. C., Joaquim, H. P. G., Pedrazzi, J. F. C., Pain, A. de O., Duque, G., & Aprahamian, I. (2022). Cannabinoids in late life Parkinson's disease and dementia: Biological pathways and clinical challenges. *Brain Sciences*, 12(12), Article 1596. <https://doi.org/10.3390/brainsci12121596>

Gundugurti, P. R., Banda, N., Yadlapalli, S. S. R., Narala, A., Thatikonda, R., Kocherlakota, C., & Kothapalli, K. S. D. (2024). Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double-blind multicenter randomized clinical trial. *Asian Journal of Psychiatry*, 97, 104073. <https://doi.org/10.1016/j.ajp.2024.104073>

Melas, P. A., Scherma, M., Fratta, W., Cifani, C., & Fadda, P. (2021). Cannabidiol as a potential treatment for anxiety and mood disorders: Molecular targets and epigenetic insights from preclinical research. *International Journal of Molecular Sciences*, 22(4), 1863. <https://doi.org/10.3390/ijms22041863>

Miao, Y., Zhao, F., & Guan, W. (2025). A novel insight into the antidepressant effect of cannabidiol: Possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors. *International Journal of Neuropsychopharmacology*, 28(2), pyae064. <https://doi.org/10.1093/ijnp/pyae064>

Pautex, S., Bianchi, F., Daali, Y., Augsburger, M., de Saussure, C., Wampfler, J., Curtin, F., Desmeules, J., & Broers, B. (2022). Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients. *Frontiers in Aging Neuroscience*, 14, Article 957665. <https://doi.org/10.3389/fnagi.2022.957665>

Silote, G. P., Sartim, A., Sales, A., Eskelund, A., Guimarães, F. S., Wegener, G., Joca, S., School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP), University of São Paulo (USP), Brazil, Translational Neuropsychiatry Unit (TNU), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, School of Medicine of Ribeirão Preto (FMRP), University of São Paulo (USP), Brazil, & Aarhus Institute of Advanced Studies (AIAS), Aarhus University, Denmark. (2019). Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. In *Journal of Chemical Neuroanatomy*. <https://doi.org/10.1016/j.jchemneu.2019.04.006>

Walther, S., & Halpern, M. (2010). Cannabinoids and dementia: A review of clinical and preclinical data. *Pharmaceuticals*, 3(8), 2689–2708. <https://doi.org/10.3390/ph3082689>

Wright, M., Di Ciano, P., & Brands, B. (2020c). Use of cannabidiol for the treatment of anxiety: A short synthesis of Pre-Clinical and clinical evidence. *Cannabis and Cannabinoid Research*, 5(3), 191–196. <https://doi.org/10.1089/can.2019.0052>

Pain Management

Argueta, D. A., Ventura, C. M., Kiven, S., Varun, S., & Gupta, K. (2020). A Balanced Approach for Cannabidiol Use in Chronic Pain. *Frontiers in Pharmacy*, 11(561). <https://doi.org/10.3389/fphar.2020.00561>

Barrie, N., & Manolios, N. (2017b). The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. *European Journal of Rheumatology*, 4(3), 210–218. <https://doi.org/10.5152/eurjrheum.2017.17025>

Bakewell, B. K., Sherman, M., Binsfeld, K., Ilyas, A. M., Stache, S. A., Sharma, S., Stolzenberg, D., & Greis, A. (2022). The use of cannabidiol in patients with low back pain caused by lumbar spinal stenosis: an observational study. *Cureus*. <https://doi.org/10.7759/cureus.29196>

Boehnke, K. F., Gagnier, J. J., Matallana, L., & Williams, D. A. (2021). Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey. *The Journal of Pain*. <https://doi.org/10.1016/j.jpain.2020.12.001>

Frane, N., Stapleton, E., Iturriaga, C., Ganz, M., Rasquinha, V., & Duarte, R. (2022). Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study. *Journal of Cannabis Research*, 4(1). <https://doi.org/10.1186/s42238-022-00154-9>

Huang, A., Stolzenberg, L., Usman, M., Awan, M., Bruner, P., & Macgregor, G. (2025). A Survey on the Use of Cannabidiol (CBD) Isolate, Its Perceived Benefits, and Associated Side Effects Among Subjects With Chronic Pain. *Cureus, Inc.*. <https://doi.org/10.7759/cureus.80198>

Lowin, T., Tingting, R., Zurmahr, J., Classen, T., Schneider, M., & Pongratz, G. (2020). Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. *Cell Death and Disease*, 11(8). <https://doi.org/10.1038/s41419-020-02892-1>

Strand, N. H., Maloney, J., Kraus, M., Wie, C., Turkiewicz, M., Gomez, D. A., Adeleye, O., & Harbell, M. W. (2023b). Cannabis for the Treatment of Fibromyalgia: A Systematic review. *Biomedicines*, 11(6), 1621. <https://doi.org/10.3390/biomedicines11061621>

Vuckovic, S., Srebro, D., Vujovic, K. S., Vucetic, C., & Prostran, M. (2018). Cannabinoids and Pain: New Insights from Old Molecules. *Frontiers in Pharmacology*, 9(9). <https://doi.org/10.3389/fphar.2018.01259>

General CBD

Balachandran, P., Elsohly, M., & Hill, K. P. (2021). Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. *Journal of General Internal Medicine*, 36(7), 2074–2084. <https://doi.org/10.1007/s11606-020-06504-8>

Campos, A. C., & Guimarães, F. S. (2008c). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. *Psychopharmacology*, 199(2), 223–230. <https://doi.org/10.1007/s00213-008-1168-x>

Greenwich Biosciences. (n.d.). HIGHLIGHTS OF PRESCRIBING INFORMATION. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/2103651bl.pdf

Hosseini, A., McLachlan, A. J., & Lickliter, J. D. (2020). A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. *British Journal of Clinical Pharmacology*, 87(4), 2070–2077. <https://doi.org/10.1111/bcp.14617>

Naya, N. M., Kelly, J., Corna, G., Golino, M., Abbate, A., & Toldo, S. (2023c). Molecular and cellular mechanisms of action of cannabidiol. *Molecules*, 28(16), 5980. <https://doi.org/10.3390/molecules28165980>

Anti-Addiction & Detox Support

Arnold, J. C., McCartney, D., Suraev, A., & McGregor, I. S. (2023). The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. *Clinical and Translational Science*, 16(1), 10–30. <https://doi.org/10.1111/cts.13425>

Bosquez-Berger, T., Gudorf, J. A., Kuntz, C. P., Desmond, J. A., Schleich, J. P., VanNieuwenhze, M. S., & Straiker, A. (2023). Structure–Activity relationship study of Cannabidiol-Based analogs as negative allosteric modulators of the M-Opioid receptor. *Journal of Medicinal Chemistry*, 66(14), 9466–9494. <https://doi.org/10.1021/acs.jmedchem.3c00061>

Galaj, E., & Xi, Z. (2020). Possible receptor mechanisms underlying cannabidiol effects on addictive-like behaviors in experimental animals. *International Journal of Molecular Sciences*, 22(1), 134. <https://doi.org/10.3390/ijms22010134>

Gasparyan, A., Navarrete, F., Navarro, D., & Manzanares, J. (2023). Cannabidiol regulates behavioral and brain alterations induced by spontaneous alcohol withdrawal. *Neuropharmacology*, 233, 109549. <https://doi.org/10.1016/j.neuropharm.2023.109549>

Hurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. (2019). Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. *American Journal of Psychiatry*, 176(11), 911–922. <https://doi.org/10.1176/appi.ajp.2019.18101191>

Hurd, Y. L., Yoon, M., Manini, A. F., Hernandez, S., Olmedo, R., Ostman, M., & Jutras-Aswad, D. (2015). Early phase in the development of cannabidiol as a treatment for addiction: Opioid relapse takes initial center stage. *Neurotherapeutics*, 12(4), 807–815. <https://doi.org/10.1007/s13311-015-0373-7>

Nona, C. N., Hendershot, C. S., & Foll, B. L. (2019b). Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research. *Experimental and Clinical Psychopharmacology*, 27(4), 359–369. <https://doi.org/10.1037/pha0000272>

Sagheddu, C., Muntoni, A. L., Pistis, M., & Melis, M. (2015). Endocannabinoid signaling in motivation, reward, and addiction. *International Review of Neurobiology*, 257–302. <https://doi.org/10.1016/bs.irn.2015.10.004>

Wiese, B., & Wilson-Poe, A. R. (2018). Emerging evidence for cannabis' role in opioid use Disorder. *Cannabis and Cannabinoid Research*, 3(1), 179–189. <https://doi.org/10.1089/can.2018.0022>

Zimmermann, S., Teetzmann, A., Baeßler, J., Schreckenberger, L., Zaiser, J., Pfisterer, M., Stenger, M., & Bach, P. (2024). Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: The double-blind randomized controlled ICONIC trial. *Molecular Psychiatry*. Advance online publication. <https://doi.org/10.1038/s41380-024-02869-y>